Mentari Therapeutics, Inc. (MTRI)
14.70
-0.54
(-3.57%)
USD |
NASDAQ |
Nov 20, 16:00
14.48
-0.22
(-1.50%)
After-Hours: 20:00
Mentari Therapeutics Research and Development Expense (TTM) : 2.665M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.665M |
| June 30, 2026 | 3.034M |
| March 31, 2026 | 2.806M |
| December 31, 2025 | 2.209M |
| September 30, 2025 | 2.638M |
| June 30, 2025 | 2.834M |
| March 31, 2025 | 3.463M |
| December 31, 2024 | 3.695M |
| September 30, 2024 | 3.244M |
| June 30, 2024 | 3.765M |
| March 31, 2024 | 3.182M |
| December 31, 2023 | 3.404M |
| September 30, 2023 | 3.646M |
| June 30, 2023 | 3.732M |
| March 31, 2023 | 4.609M |
| December 31, 2022 | 5.484M |
| September 30, 2022 | 7.17M |
| June 30, 2022 | 7.283M |
| March 31, 2022 | 7.498M |
| December 31, 2021 | 7.517M |
| September 30, 2021 | 5.70M |
| June 30, 2021 | 5.120M |
| March 31, 2021 | 4.371M |
| December 31, 2020 | 3.874M |
| September 30, 2020 | 4.678M |
| Date | Value |
|---|---|
| June 30, 2020 | 5.561M |
| March 31, 2020 | 6.457M |
| December 31, 2019 | 6.436M |
| September 30, 2019 | 5.642M |
| June 30, 2019 | 4.327M |
| March 31, 2019 | 2.911M |
| December 31, 2018 | 2.096M |
| September 30, 2018 | 1.694M |
| June 30, 2018 | 1.515M |
| March 31, 2018 | 1.350M |
| December 31, 2017 | 1.043M |
| September 30, 2017 | 0.8412M |
| June 30, 2017 | 0.5339M |
| March 31, 2017 | 0.2965M |
| December 31, 2016 | 0.2116M |
| September 30, 2016 | 0.2103M |
| June 30, 2016 | 0.2853M |
| March 31, 2016 | 0.5112M |
| December 31, 2015 | 0.8553M |
| September 30, 2015 | 0.7974M |
| June 30, 2015 | 0.7735M |
| March 31, 2015 | 0.5328M |
| December 31, 2014 | 0.155M |
| September 30, 2014 | 0.1014M |
| June 30, 2014 | 0.057M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Liquidia Corp. | 70.90M |
| Johnson & Johnson | 16.02B |
| Eli Lilly & Co. | 15.38B |
| Merck & Co., Inc. | 27.55B |
| ANI Pharmaceuticals, Inc. | 50.60M |